Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| BIOGEN INC.BIIB · Entity 1675 | EVP & Chief Financial Officer | February 12, 2020 | February 14, 2020 |
| Decoy Therapeutics Inc.FLKS · Entity 937 | Director | July 26, 2017 | July 27, 2017 |
| NEOGEN CORPNEOG · Entity 4338 | Director | October 01, 2026 | October 02, 2026 |
| Tempest Therapeutics, Inc.OVAS · Entity 7734 | Director | July 04, 2018 | July 06, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 10,865 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 10,865 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
BIOGEN INC.
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,118 |
Ending reported balance
After 2020-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-02-12 · Exercise / conversion · Acquired 1,919 · Balance 3,732 Row 2 · 2020-02-12 · Tax withholding · Disposed 614 · Balance 3,118 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-02-12 | Direct | 10,550 |
Reported balance
After 2020-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-12 · Grant · Acquired 10,550 · Balance 10,550 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-12 | Direct | 10,601 |
Reported balance
After 2020-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-12 · Exercise / conversion · Disposed 1,919 · Balance 10,601 F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-02-12 | Direct | 8,348 |
Reported balance
After 2020-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-12 · Other · Disposed 2,253 · Balance 8,348 F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Decoy Therapeutics Inc.
Report date July 26, 2017 · Filed July 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2027-07-26 | Direct | 12,000 |
Reported balance
After 2017-07-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-26 · Grant · Acquired 12,000 · Balance 12,000 F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017.
NEOGEN CORP
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 42,306 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 9,804 · Balance 42,306 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.24 · Expires 2036-10-01 | Direct | 20,558 |
Reported balance
After 2026-10-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-01 · Grant · Acquired 20,558 · Balance 20,558 F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants |
Filing footnotes · ownership attribution and instrument terms
F1: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants
Tempest Therapeutics, Inc.
Report date July 04, 2018 · Filed July 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2028-07-04 | Direct | 12,000 |
Reported balance
After 2018-07-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-04 · Grant · Acquired 12,000 · Balance 12,000 F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 2, 2026 18:58 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 20,558 | $0.00 Strike: $12.24 | $0.00 |
DisclosureSEC source: 0000711377-26-000022 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,558 Underlying: Common Stock · 20,558 shares Expires 2036-10-01 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 01, 2026 Filed Oct 2, 2026 18:58 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantRestricted Stock Units | 9,804 | $12.24 | $120,000.96 |
DisclosureSEC source: 0000711377-26-000022 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,306 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 14,950 | $0.00 Strike: $34.16 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · derivative · entry 4 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,950 Underlying: Common stock · 14,950 shares Expires 2036-06-18 F4 · derivative.exercise_date: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · derivative · entry 3 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,927 Underlying: Common stock · 2,927 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F3 · derivative.expiration_date: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,816 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:24 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000105 · wk-form4_1782249875.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2026 Filed Jun 16, 2026 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000075 · wk-form4_1781640401.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 1,976 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2026 Filed Jun 16, 2026 20:06 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-26-000075 · wk-form4_1781640401.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,049 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 13:52 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 2,025 | $6.19 Strike: $6.19 | $12,534.75 |
DisclosureSEC source: 0000711377-25-000060 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,050 Underlying: Common Stock · 2,025 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 13:52 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock | 2,025 | $6.19 | $12,534.75 |
DisclosureSEC source: 0000711377-25-000060 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 14:08 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 1,777 | $6.19 Strike: $6.19 | $10,999.63 |
DisclosureSEC source: 0000711377-25-000071 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,777 Underlying: Common Stock · 1,777 shares Expires 2025-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 14:08 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock | 1,777 | $6.19 | $10,999.63 |
DisclosureSEC source: 0000711377-25-000071 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 19:45 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 50,814 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000711377-25-000051 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,814 Underlying: Common Stock · 50,814 shares Expires 2035-10-23 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 23, 2025 Filed Oct 27, 2025 19:45 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock | 19,769 | $6.07 | $119,997.83 |
DisclosureSEC source: 0000711377-25-000051 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,469 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 20:48 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 2,071 | $5.63 Strike: $5.63 | $11,659.73 |
DisclosureSEC source: 0000711377-25-000037 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,071 shares Expires 2025-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2025 Filed Oct 9, 2025 20:48 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock | 2,071 | $5.63 | $11,659.73 |
DisclosureSEC source: 0000711377-25-000037 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000059 · wk-form4_1750710331.xml · derivative · entry 4 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,120 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F4 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000059 · wk-form4_1750710331.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 15,768 | $0.00 Strike: $35.50 | $0.00 |
DisclosureSEC source: 0001439222-25-000059 · wk-form4_1750710331.xml · derivative · entry 3 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,768 Underlying: Common stock · 15,768 shares Expires 2035-06-18 F3 · derivative.exercise_date: These options were granted on June 18, 2025. The shares underlying this option vest as to 100% of the underlying shares on June 18, 2026. Read SEC document |
| June 18, 2025 Filed Jun 23, 2025 20:25 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000059 · wk-form4_1750710331.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,861 Underlying: Common stock · 2,861 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000045 · wk-form4_1750191390.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,976 Underlying: Common stock · 1,977 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2025 Filed Jun 17, 2025 20:16 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-25-000045 · wk-form4_1750191390.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2025 Filed Apr 22, 2025 19:37 UTC | NEOGEN CORP NEOG · Entity 4338 | PurchaseCommon Stock | 20,712 | $4.84 | $100,217.08 |
DisclosureSEC source: 0000711377-25-000007 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,629 Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 17:26 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 1,776 | $13.81 Strike: $13.81 | $24,526.56 |
DisclosureSEC source: 0000711377-24-000051 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,552 Underlying: Common Stock · 1,776 shares Expires 2024-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 17:26 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock | 1,776 | $13.81 | $24,526.56 |
DisclosureSEC source: 0000711377-24-000051 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 14:28 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantCommon Stock (Right to Buy) · Derivative | 18,653 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0000711377-24-000039 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,653 Underlying: Common Stock · 18,653 shares Expires 2031-10-24 F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 24, 2024 Filed Oct 28, 2024 14:28 UTC | NEOGEN CORP NEOG · Entity 4338 | GrantRestricted Stock Units | 6,075 | $13.58 | $82,498.50 |
DisclosureSEC source: 0000711377-24-000039 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,840 F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:25 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 2,070 | $15.07 Strike: $15.07 | $31,194.90 |
DisclosureSEC source: 0000711377-24-000028 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,071 Underlying: Common Stock · 2,070 shares Expires 2024-10-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2024 Filed Oct 9, 2024 17:25 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock | 2,070 | $15.07 | $31,194.90 |
DisclosureSEC source: 0000711377-24-000028 · primary_doc.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,141 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 11,774 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001439222-24-000107 · wk-form4_1719259827.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,774 Underlying: Common stock · 11,774 shares Expires 2034-06-20 F3 · derivative.exercise_date: This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 2,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000107 · wk-form4_1719259827.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,120 Underlying: Common stock · 2,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 1,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000075 · wk-form4_1718658827.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,953 Underlying: Common stock · 1,976 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:13 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 1,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-24-000075 · wk-form4_1718658827.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,976 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2023 Filed Oct 31, 2023 20:21 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 5,329 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0000711377-23-000023 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,470 Underlying: Common Stock · 5,329 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 26, 2023 Filed Oct 31, 2023 20:21 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock (Right to Buy) · Derivative | 13,716 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0000711377-23-000023 · primary_doc.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,132 Underlying: Common Stock · 13,716 shares Expires 2030-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 33,177 | $0.00 Strike: $26.56 | $0.00 |
DisclosureSEC source: 0001439222-23-000087 · wk-form4_1686861037.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,177 Underlying: Common stock · 33,177 shares Expires 2033-06-13 F3 · derivative.exercise_date: This option was granted on June 13, 2023. The shares underlying this option vest as to 25% of the underlying shares on June 13, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:30 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 5,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-23-000087 · wk-form4_1686861037.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,929 Underlying: Common stock · 5,929 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on June 13, 2023. Beginning on June 13, 2024, the shares underlying the stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:03 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionRestricted Stock Units · Derivative | 6,212 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000711377-22-000023 · primary_doc.xml · derivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,212 Underlying: Common Stock · 6,212 shares Expires 2025-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:03 UTC | NEOGEN CORP NEOG · Entity 4338 | Exercise / conversionCommon Stock (Right to Buy) · Derivative | 18,416 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000711377-22-000023 · primary_doc.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,416 Underlying: Common Stock · 18,416 shares Expires 2029-10-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:27 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 2,253 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005773 · form4.xml · derivative · entry 5 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,348 Underlying: Common Stock · 2,253 shares Expires 2022-02-12 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,919 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005773 · form4.xml · derivative · entry 4 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,601 Underlying: Common Stock · 1,919 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:27 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,550 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005773 · form4.xml · derivative · entry 3 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,550 Underlying: Common Stock · 10,550 shares Expires 2023-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 614 | $331.76 | $203,700.64 |
DisclosureSEC source: 0001127602-20-005773 · form4.xml · nonDerivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,118 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:27 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005773 · form4.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,690 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001123 · form4.xml · derivative · entry 4 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,996 Underlying: Common Stock · 1,690 shares Expires 2021-01-02 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,302 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001123 · form4.xml · derivative · entry 3 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,686 Underlying: Common Stock · 1,302 shares Expires 2021-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 406 | $294.20 | $119,445.20 |
DisclosureSEC source: 0001127602-20-001123 · form4.xml · nonDerivative · entry 2 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,813 Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:14 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,302 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-001123 · form4.xml · nonDerivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:05 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 12,520 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006075 · form4.xml · derivative · entry 1 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,520 Underlying: Common Stock · 12,520 shares Expires 2022-02-12 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:17 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,661 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-001282 · form4.xml · derivative · entry 4 CAPELLO JEFFREY D · CIK 0001224108 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,988 Underlying: Common Stock · 1,661 shares Expires 2021-01-02 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.